Please login to the form below
Biocon
This page shows the latest Biocon news and features for those working in and with pharma, biotech and healthcare.
Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA
Amgen launched its Kamjinti there in July, with Biocon and Mylan reaching the market with their Ogivri biosimilar in December, and others are in the latter stages of regulatory review.
Latest news
-
Mylan, Biocon’s Herceptin biosimilar launched in US
Mylan and Biocon have launched their biosimilar Herceptin (trastuzumab) under the brand name Ogivri, after Roche tried and failed to get an injunction on sales of biosimilars in the US. . ... Mylan/Biocon’s Herceptin biosimilar is the second to
-
Amgen CEO says Aimovig is “one of most successful launches”
of weakness from biosimilar competition after Mylan/Biocon launched their Fulphila rival in July.
-
Roche eyes September FDA verdict for triple NSCLC therapy
Amgen and Allergan’s Mvasi biosimilar was cleared by the FDA last September, while Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan also have biosimilars in late-stage development.
-
Novartis doubles down on biosimilars with Biocon alliance
The companies will develop multiple immunology and oncology biosimilars. Already a big player in the emerging biosimilars market, Novartis has struck a deal with India’s Biocon in a bid to ... globally”. The deal with Novartis' subsidiary Sandoz
-
Mylan gets first biosimilar Herceptin OK from FDA
The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin ... Mylan said in a statement Ogivri is the
Mylan, Biocon’s Herceptin biosimilar launched in US
Amgen CEO says Aimovig is “one of most successful launches”
Roche eyes September FDA verdict for triple NSCLC therapy
Novartis doubles down on biosimilars with Biocon alliance
More from news
Approximately 10 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Deal Watch May 2016
Similarly, Bristol-Myers Squibb has called time on its deal with Biocon for IN-105/Tregopil [oral insulin]. ... Given the cost of the clinical studies going forwards, Biocon will now be seeking a new partner.
-
Pharma deals during February 2013
Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... Mylan and Biocon will share development and
Deal Watch May 2016
Pharma deals during February 2013
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- US demand for COVID-19 antibody treatments rising fast
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Sandoz completes acquisition of GSK’s cephalosporin business
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Best practice in UK diabetes care recognised at prestigious national awards
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- US demand for COVID-19 antibody treatments rising fast
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- David Hunt launches independent agency The Considered
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
PMHub
Mednet Group
Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
